Top

Published in:

01-10-2008 | Special Feature

Estrogen signaling pathway and hormonal therapy

Authors: Shin-ichi Hayashi, Yuri Yamaguchi

Published in: Breast Cancer | Issue 4/2008

Abstract

Hormonal therapy, such as estrogen-targeting therapy, has undergone remarkable development in recent several years, using drugs such as LH–RH agonists, new SERMs and third-generation aromatase inhibitors. Several ongoing large-scale international clinical trials for hormonal therapy are establishing the standard protocol for treatments with these drugs. On the other hand, there have been attempts to predict the individual efficacy of hormonal therapy using classical molecular biomarkers such as ER and PgR. However, approximately one-third of ERα-positive patients do not respond to endocrine therapy, while some ERα-negative patients are responsive. These discrepancies may be due to the different estrogen-related intracellular signaling pathways in breast cancer cells. Furthermore, the ineffectiveness of hormonal therapy in some individuals (due to, for example, aromatase inhibitor resistance) may be caused by these mechanisms. In this paper, we discuss the molecular mechanisms of these different responses to hormonal therapies and their implications for the estrogen signaling pathway in breast cancer cells. Furthermore, we touch upon basic studies into predicting the efficacy of hormonal therapy and new strategies in this field.

Hayashi S, Eguchi H, Tanimoto K, Yoshida T, Omoto Y, Inoue A, et al. The expression and function of estrogen receptor α and β in human breast cancer and its clinical application. Endocr Relat Cancer. 2003;10:193–202.PubMedCrossRef

Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol. 2005;19:1951–9.PubMedCrossRef

Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol. 2005;19:833–42.PubMedCrossRef

Norman AW, Mizwicki MT, Norman DP. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev. 2004;3:27–41.

Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005;11:865s–70s.PubMed

Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem. 1994;269:4458–66.PubMed

Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995;270:1491–4.PubMedCrossRef

Smith CL, O’Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev. 2004;25:45–71.PubMedCrossRef

Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, a steroid receptor coactivtor amplified in breast and ovarian cancer. Science. 1997;277:965–8.PubMedCrossRef

10.

Brown AMC, Jeltsch JM, Roberts M, Chambon P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci USA. 1984;81:6344–8.PubMedCrossRef

11.

Westley B and Rochefort H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell. 1980;20:353–62.CrossRef

12.

Inoue S, Orimo A, Hosoi T, et al. Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc Natl Acad Sci USA. 1993;90:11117–21.PubMedCrossRef

13.

Inoue A, Omoto Y, Yamaguchi Y, Kiyama R, Hayashi S. Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cell. J Mol Endocrinol. 2004;32:649–61.PubMedCrossRef

14.

Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, et al. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem. 2002;277:24353–60.PubMedCrossRef

15.

Bruning JC, Lingohr P, Gillette J, Hanstein B, Avci H, Krone W, et al. Estrogen receptor-alpha and Sp1 interact in the induction of the low density lipoprotein-receptor. J Steroid Biochem Mol Biol. 2003;86:113–21.PubMedCrossRef

16.

Kalaitzidis D, Gilmore TD. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab. 2005;16:46–52.PubMedCrossRef

17.

Kato S, Masuhiro Y, Watanabe M, Kobayashi Y, Takeyama K, Endoh H, et al. Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. Genes Cells. 2000;5:593–601.PubMedCrossRef

18.

Bunone G, Briand P-A, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996;15:2174–83.PubMed

19.

Amold SF, Obourn JD, Jaffe H, Notides AC. Ser 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endocrinol. 1994;8:1208–14.CrossRef

20.

Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA. pp90srk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol. 1998;18:1978–84.PubMed

21.

Rowan BG, Weigel NL, O’Malley BW. Phosphorylation of steroid receptor coactivator-1: indentification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J Biol Chem. 2000;275:4475–83.PubMedCrossRef

22.

Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol. 2000;20:5041–7.CrossRef

23.

Yamashita H, Nishino M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, et al. Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res. 2005;7:753–64.CrossRef

24.

Razandi M, Pedram A, Greene GL, Levin ER. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERα and ERβ expressed in Chinese hamster ovary cells. Mol Endocrinol. 1999;13:307–19.PubMedCrossRef

25.

Harrington WR, Kim SH, Funk CC, Madak-Erdogan Z, Schiff R, Katzenellenbogen JA, et al. Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocrinol. 2005;20:491–502.PubMedCrossRef

26.

Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, Santen RJ. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane. Proc Natl Acad Sci USA. 2004;101:2076–81.PubMedCrossRef

27.

Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cell. Endocrinol. 2004;146:624–32.CrossRef

28.

Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, et al. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004;279:27008–16.PubMedCrossRef

29.

Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol. 2006;20:1996–2009.PubMedCrossRef

30.

Razandi M, Oh P, Pedram A, Schnitzer J, Levin ER. ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol. 2002;16:100–15.PubMedCrossRef

31.

Barletta F, Wong CW, McNally C, Komm BS, Katzenellenbogen B, Cheskis BJ. Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Mol Endocrinol. 2004;18:1096–108.PubMedCrossRef

32.

Acconcia F, Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett. 2005;238:1–14.PubMedCrossRef

33.

Kumar R, Wang RA, Mazumdar A, Talukder AH, Mandal M, Yang Z, et al. A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature. 2002;418:654–7.PubMedCrossRef

34.

Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor α in breast cancer cells. Clin Cancer Res. 2004;10:3621–8.PubMedCrossRef

35.

Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang AH, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17–32.PubMedCrossRef

36.

Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335–48.PubMedCrossRef

37.

Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392–401.PubMedCrossRef

38.

O’Neill JS, Miller WR. Aromatase activity in breast adipose tissue from women with benign and malignant breast disease. Br J Cancer. 1987;56:601–4.PubMed

39.

Santen RJ, Santner SJ, Pauley RJ, Tait L, Kaseta J, Demers LM, et al. Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? J Steroid Biochem Mol Biol. 1997;61:267–71.PubMedCrossRef

40.

Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology. 2001;142:4589–94.PubMedCrossRef

41.

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–2.PubMedCrossRef

42.

Yamaguchi Y, Takei H, Suemasu K, Kobayashi Y, Kurosumi M, Harada N, et al. Tumor–stromal interaction through the estrogen-signaling pathway in human breast cancer. Cancer Res. 2005;65:4653–62.PubMedCrossRef

43.

Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R, et al. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol. 2002;29:175–92.PubMedCrossRef

44.

Yoshida N, Omoto Y, Inoue A, Eguchi H, Kobayashi Y, Kurosumi M, et al. Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci. 2004;95:496–502.PubMedCrossRef

45.

Harvell DME, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008; in press.

Title: Estrogen signaling pathway and hormonal therapy
Authors: Shin-ichi Hayashi
Yuri Yamaguchi
Publication date: 01-10-2008
Publisher: Springer Japan
Published in: Breast Cancer / Issue 4/2008
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-008-0070-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2008

New preoperative MRI marking technique for a patient with ductal carcinoma in situ

Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature

Intratumoral estrogen production in breast carcinoma: significance of aromatase

Usefulness and limitations of the Japan Mammography Guidelines for the categorization of microcalcifications

Acknowledgement to reviewers 2008

Surgical treatment for chest wall invasion due to the local recurrence of breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer